A randomized, double blind, phase III clinical trial, to evaluate the ability of the CV638 attenuated live vaccine candidate Vibrio cholerae 638 O1 El Tor Ogawa strain, to prevent clinical cholera disease caused by the challenge with the virulent strain Vibrio cholerae 3008 . - PVSVCHO

Finlay Institute of Vaccines (IFV)0 sites120 target enrollmentDecember 29, 2016

Overview

No summary available.

Registry

who.int

Start Date

December 29, 2016

End Date

TBD

Last Updated

last year

Study Type

Interventional

Sex

All

Sponsor

Finlay Institute of Vaccines (IFV)

•1\. Woman or man from 18 to 45 years of age.
•2\. Voluntariness expressed through written informed consent signed by the volunteer.
•3\. Good physical and mental state established by medical criteria by means of anamnesis and physical examination, as well as by electrocardiogram and the following complementary ones: complete blood count with erythrocyte sedimentation, hemoglobin: glycemia, creatinine, urea, uric acid, TGO, TGP, GGT, Alkaline phosphatase, and urine (cituria), within the reference parameters which were not clinically significant, before starting the study.
•4\. Women of childbearing age who meet the following criteria:
•A.Negative pregnancy rapid test in the previous checkup, before vaccination and before the challenge,
•B. Agree to practice sexual abstinence or use an approved effective method of birth control within 2 months after vaccination,
•C. Agree to continue these precautions during the study and up to 30 days after the challenge.
•5\. Man of childbearing age who agrees not to conceive a child within 30 days of vaccination.
•6\. Subject that agrees not to participate in another clinical trial during the period.

•1\. Volunteers with VC titers greater than or equal to 320, five days before administration of CV638 or Placebo.
•2\. Volunteers seropositive to cholera antitoxin IgG by ELISA 10 days before CV638 or Placebo administration.
•3\. Acute disease detected in the week prior to the administration of CV638, Placebo.
•4\. Axillary temperature \= 37\.5 ° C immediately prior to administration of CV638 or Placebo.
•5\. Personal history of chronic illness, except compensated asthma and hypertension.
•6\. History of immunosuppressive therapy (systemic steroids, cytostatics, etc.) or immunostimulants (interferons, transfer factor, gammaglobulins, levamisole, etc.) in the previous 30 days, excluding topical steroids or by inhalation.
•7\. History of therapy with immunoglobulins or blood products during the 6 months prior to administration of CV638 or Placebo.
•8\. History of antibiotic therapy, current or during the 10 days prior to administration of CV638, or Placebo.
•9\. History of cholera in the last 3 years.
•10\. History of immunization with cholera vaccines prior to the first intervention.